We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eirx Therap. | LSE:ERX | London | Ordinary Share | GB00B0XQBS97 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.015 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:1455O
EiRx Therapeutics PLC
15 February 2008
EIRX THERAPEUTICS PLC
( "EiRx" or "the Company" )
Funding package
The Directors of Eirx Therapeutics plc are pleased to announce that EiRx has
agreed in principle a funding package designed to provide working capital to
fund the Company until at least 31 December 2008 comprising a placing of shares,
convertible loan stock and an enlarged bank facility along with some short term
funding.
The details of the funding package are being finalised and will be announced no
later than Thursday 21 February 2008.
For further information, please contact:
EiRx Therapeutics plc +353 (0)21 432 0847
Colin Telfer PhD, Chief Executive Officer
Grant Thornton Corporate Finance +44 (0)20 7383 5100
Philip Secrett / Colin Aaronson
About EiRx
EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing
cutting-edge targeted therapies for the treatment of cancer. EiRx is
headquartered in Cork, Ireland, conducts drug discovery from its laboratories in
Cork and in Aberdeen, Scotland. The Company has an initial focus on tumours
arising due to anomalies in apoptosis and cellular growth regulatory pathways,
with particular relation to breast and colorectal tumours, currently two of the
four leading causes of death from cancer world-wide.
EiRx is built on leading scientific expertise in the areas of apoptosis biology,
cancer pathway biology, biomarker technologies and the metabolic basis of drug
resistance in tumours. It has established technical capabilities in target
identification, validation and cell-based screening, and is combining unique
resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional
genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic
cellular screening technology to create a product development engine
specialising in discovery and development of small-molecule targeted cancer
therapies and the discovery and validation of cancer biomarkers.
For further information please see our website at http://www.eirx.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZGGMZVKRGRZM
1 Year Eirx Therapeutics Chart |
1 Month Eirx Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
